TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04255212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic treatment
Description: Participants will be asked to lay supine on a medical table and keep their arms relaxed. 30 repetitions of gentle upper limb nerves mobilization, performed through a combination of neck and arm physiological movements, will be administered with cycles of tensions and relaxation of 1/5 seconds for 3 minutes in total for each arm. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
Study: NCT03731975

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTZ Paste
Description: Tooth allocated to this group will be treated with CTZ paste, according to the Cappielo's protocol (1964), updated by Moura et al. (2016).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GP Paste
Description: Tooth allocated to this group will be treated with Guedes-Pinto paste, according to the Guedes-Pinto's protocol (1981), updated by Mello-Moura et al. (2011).
Study: NCT02274311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate
Description: Clomiphene citrate, 50 mg, orally for three months
Study: NCT03175159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPACT
Description: Ten counseling sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Two counseling sessions
Study: NCT00822120

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bleomycin sulfate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Study: NCT01731808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing counseling
Description: The participants who were randomized in the intervention group received outpatient physician-prescribed wound care. Additionally, they received standardized education regarding diabetic foot care. The nurse-led outpatient intervention started a few days after randomization and went on for five weeks. The study nurses conducting the interventions were wound care nurses and trained in foot examination, foot care, education, and counseling. During a period of five weeks, the participants were provided with weekly, one-hour education, skill training, and counseling sessions on foot care. Each participant received a foot care kit with essential foot care material and a foot care diary.
Study: NCT01261494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 80mg
Description: hard gelatin capsules dosed at 20mg,oral administration,4 capsules per day before breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: hard gelatin capsules,oral administration,4 capsules per day before breakfast
Study: NCT03614702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1-dose cIPV + 2-doses bOPV (Candy)
Description: Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1-dose sIPV + 2-doses bOPV (Candy)
Description: Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
Study: NCT03614702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses cIPV + 1-dose bOPV (Candy)
Description: Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses sIPV + 1-dose bOPV (Candy)
Description: Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses cIPV + 1-dose tOPV (Candy)
Description: Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses sIPV + 1-dose tOPV (Candy)
Description: Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1-dose cIPV + 2-doses bOPV (Liquid)
Description: Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1-dose sIPV + 2-doses bOPV (Liquid)
Description: Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
Study: NCT03267433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET or PET/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab and Hyaluronidase Human
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab and Hyaluronidase Human
Description: Given SC
Study: NCT04019288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batiraxcept
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batiraxcept
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study: NCT03142841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RESCUE Problem Solving Intervention
Description: This is an education and support intervention for caregivers of Veterans with stroke. The investigators will teach study participants about the COPE model of problem solving and guide them through the application of this model in their caregiver role. They will receive tailored stroke education.
Study: NCT02982772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Therapy
Description: Brief behavioral intervention~The test product is a transdermal nicotine patch for 12 weeks. The dosage of the test product depends on the new algorithm (amount, addiction, prior attempts) Nicotine Gums for 12 weeks.
Study: NCT00812578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 8 tablets equivalent to 280 micrograms for 2 weeks and 4 tablets equivalent to 140 micrograms for 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: 8 tablets equivalent to 280 micrograms for 2 weeks and 4 tablets equivalent to 140 micrograms for 10 weeks
Study: NCT03292588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab administered every 4 weeks by subcutaneous injection at a dose of:~* 100 mg for participants ≥12 years of age and~* 40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered every 4 weeks by subcutaneous injection at a dose of:~* 100 mg for participants ≥12 years of age and~* 40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study.
Study: NCT00765050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD133+ cells transplant
Description: intramuscular administration of CD133+ cells that have been mobilized from peripheral blood.
Study: NCT00592384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine XR
Description: Once daily oral dose of venlafaxine XR ranging from 37.5 mg up to 300 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once daily oral dose of placebo ranging from 37.5 mg up to 300 mg
Study: NCT03527277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Naturally-sweetened orange juice
Description: Commercially-available ready-to-serve refrigerated orange juice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar-sweetened beverage
Description: Sugar-sweetened water flavored with Kool-Aid (TM)
Study: NCT00062374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG and FLT PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Undergo FLT-PET/CT
Study: NCT03614702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses cIPV + 1-dose bOPV (Liquid)
Description: Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses sIPV + 1-dose bOPV (Liquid)
Description: Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses cIPV + 1-dose tOPV (Liquid)
Description: Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
Study: NCT00062374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG and FLT PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo radical subtotal or total gastrectomy with lymph node dissection
Study: NCT04078113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pupillometer
Description: Measurements of pupillary dilatation with pupillometer to administer or not analgesia
Study: NCT03239288

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control digestible carbohydrate
Description: Single serving of control product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test resistant starch type 4
Description: Single serving of test product
Study: NCT03167840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical and Cognitive Training
Description: Physical Exercise and Cognitive Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Training
Description: Physical training alone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training alone
Study: NCT02014597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HOCD
Description: feasibility of HOCD and comparison of HOCD results between subjects with and without glaucoma

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HOCD
Description: feasibility of HOCD and comparison of HOCD results between subjects with and without glaucoma
Study: NCT01604174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Virtual Telerehabilitation (IVT)
Description: Rehabilitation after arthroplasty of knee using IVT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care rehabilitation
Description: Standard care rehabilitation after total knee arthroplasty
Study: NCT04817865

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST)
Description: M-PCR/P-AST is a dual assessment test that detects pathogenic DNA commonly associated with urinary tract infections and identifies their genotypic and phenotypic antibiotic resistance.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Culture
Description: A traditional clinical UTI evaluation consisting of non-molecular standard urine culture (SUC) and sensitivity testing methods.
Study: NCT02338440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipoprostaglandin E1
Description: Blood sampling before administration (baseline), between 1 hour to 72 hours from administration (plateau 1), 72 hours after engraftment (plateau 2), when the clinician determine to do blood sampling because of change of kidney/liver function change (optional 1), 72 hours from the change of lipoprostaglandin E1 concentration change (optional 2)
Study: NCT01432080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast 10 mg PO qhs for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort
Description: Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
Study: NCT01780636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin
Study: NCT04072302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet
Study: NCT00253045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational groups
Description: Motivational interviewing in group format
Study: NCT01029626

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopy
Description: Realization of an upper GI endoscopy
Study: NCT03983291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FaReWell Depression
Description: Facial massage and force exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: FaReWell Depression
Description: Facial massage and force exercise
Study: NCT00487773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: budesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D3 vitamin
Description: D3 vitamin
Study: NCT03614702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses sIPV + 1-dose tOPV (Liquid)
Description: Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
Study: NCT02550860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: soybean oil (SO)-based IVFE (Medialipide)
Description: The soybean oil (SO)-based IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
Study: NCT00487773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: montelukast sodium
Study: NCT02550860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fish oil (FO)-containing IVFE (Lipidem)
Description: The fish oil (FO)-containing IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
Study: NCT02587975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin
Description: 10 mg
Study: NCT01339676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colecalciferol
Description: Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Identically appearing once weekly peroral placebo capsules
Study: NCT00673218

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair
Description: 150 to 375 mg is administered SC every 2 or 4 weeks
Study: NCT00809614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: The investigational drug, AIN457 50 mg lyophilizate vials was prepared by Novartis. Reconstitution of AIN457 with 1.2 mL SWFI produced a 47 mg/mL concentrate solution for infusion from which at least 1 mL was useable. The AIN457 concentrate was diluted in 5% glucose bags for infusion through a 0.2 micron in-line filter.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to AIN457
Study: NCT02268760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILN 2061 ZW single rising doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BILN 2061 ZW fixed dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILN 2061 ZW fixed dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized breakfast
Study: NCT04946760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Manipulation
Description: The sham protocol will consist of examination of the subject's active and passive range of motion in the spine and extremities, in the joints that would have been treated with OMT. The subject will be positioned in sitting, supine and lateral recumbent in a similar manner to that of the OMT group, but without providing an active intervention.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Manipulation
Description: The sham protocol will consist of examination of the subject's active and passive range of motion in the spine and extremities, in the joints that would have been treated with OMT. The subject will be positioned in sitting, supine and lateral recumbent in a similar manner to that of the OMT group, but without providing an active intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Manipulation
Description: The sham protocol will consist of examination of the subject's active and passive range of motion in the spine and extremities, in the joints that would have been treated with OMT. The subject will be positioned in sitting, supine and lateral recumbent in a similar manner to that of the OMT group, but without providing an active intervention.
Study: NCT02144090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve measurement
Description: Fractional flow reserve measurement
Study: NCT03904862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX 4945
Description: CX-4945 is supplied as 200 mg capsules delivered orally as a formulated API

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX 4945
Description: CX-4945 is supplied as 200 mg capsules delivered orally as a formulated API

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX 4945
Description: CX-4945 is supplied as 200 mg capsules delivered orally as a formulated API
Study: NCT01731275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: A single ascending dose (SAD) administration of E6011 is administered to 8 groups as a 30-minute intravenous infusion at a dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E6011 Matching Placebo
Description: A SAD administration of E6011 Matching Placebo is administered to 2 participants in each of 8 groups as a 30-minute intravenous infusion at a placebo dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending E6011 Matching Placebo dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.